Cargando…

Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases

Orexins [orexin-A (OXA) and orexin-B (OXB)] are two isoforms of neuropeptides produced by the hypothalamus. The main biological actions of orexins, focused on the central nervous system, are to control the sleep/wake process, appetite and feeding, energy homeostasis, drug addiction, and cognitive pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Couvineau, Alain, Voisin, Thierry, Nicole, Pascal, Gratio, Valérie, Abad, Catalina, Tan, Yossan-Var
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817618/ https://www.ncbi.nlm.nih.gov/pubmed/31695678 http://dx.doi.org/10.3389/fendo.2019.00709

Ejemplares similares

The Orexin receptors: Structural and anti-tumoral properties
por: Couvineau, Alain, et al.
Publicado: (2022)

The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role
por: Couvineau, Alain, et al.
Publicado: (2018)

Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target
por: Alain, Couvineau, et al.
Publicado: (2021)

Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions
por: Couvineau, Alain, et al.
Publicado: (2021)

Editorial: GPCR in Inflammatory and Cancer Diseases
por: Couvineau, Alain, et al.
Publicado: (2020)

Systemic administration of orexin A ameliorates established experimental autoimmune encephalomyelitis by diminishing neuroinflammation
por: Becquet, Laurine, et al.
Publicado: (2019)

The Orexin-A/OX1R System Induces Cell Death in Pancreatic Cancer Cells Resistant to Gemcitabine and Nab-Paclitaxel Treatment
por: Voisin, Thierry, et al.
Publicado: (2022)

In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma
por: Dayot, Stéphanie, et al.
Publicado: (2018)

Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis
por: Tan, Yossan-Var, et al.
Publicado: (2011)

Impact of Orexin-A Treatment on Food Intake, Energy Metabolism and Body Weight in Mice
por: Blais, Anne, et al.
Publicado: (2017)

Pituitary Adenylate Cyclase Activating Peptide Deficient Mice Exhibit Impaired Thymic and Extrathymic Regulatory T Cell Proliferation during EAE
por: Tan, Yossan-Var, et al.
Publicado: (2013)

VIP Deficient Mice Exhibit Resistance to Lipopolysaccharide Induced Endotoxemia with an Intrinsic Defect in Proinflammatory Cellular Responses
por: Abad, Catalina, et al.
Publicado: (2012)

Correction: VIP Deficient Mice Exhibit Resistance to Lipopolysaccharide Induced Endotoxemia with an Intrinsic Defect in Proinflammatory Cellular Responses
por: Abad, Catalina, et al.
Publicado: (2013)

Editorial: Hypocretins/Orexins
por: López, Miguel, et al.
Publicado: (2020)

Efficiency of Orexin-A for Inflammatory Flare and Mucosal Healing in Experimental Colitis: Comparison with the Anti-TNF Alpha Infliximab
por: Blais, Anne, et al.
Publicado: (2023)

VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage
por: Abad, Catalina, et al.
Publicado: (2016)

Erratum to: VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage
por: Abad, Catalina, et al.
Publicado: (2017)

Editorial: A year in review: discussions in molecular and structural endocrinology
por: Couvineau, Alain, et al.
Publicado: (2023)

Orexins/Hypocretins: Key Regulators of Energy Homeostasis
por: Milbank, Edward, et al.
Publicado: (2019)

The Therapeutic Potential of Metformin in Neurodegenerative Diseases
por: Rotermund, Carola, et al.
Publicado: (2018)

The VPAC1 receptor: structure and function of a class B GPCR prototype
por: Couvineau, A., et al.
Publicado: (2012)

Differential Roles of Orexin Receptors in the Regulation of Sleep/Wakefulness
por: Mieda, Michihiro, et al.
Publicado: (2013)

Pharmacological Characteristics of Porcine Orexin 2 Receptor and Mutants
por: Liu, Min, et al.
Publicado: (2020)

Orexin-A Prevents Lipopolysaccharide-Induced Neuroinflammation at the Level of the Intestinal Barrier
por: Tunisi, Lea, et al.
Publicado: (2019)

The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions
por: Inutsuka, Ayumu, et al.
Publicado: (2013)

Orexin-A in Patients With Lewy Body Disease: A Systematic Review and Meta-Analysis
por: Gan, Jinghuan, et al.
Publicado: (2021)

Evidence for a Role of Orexin/Hypocretin System in Vestibular Lesion-Induced Locomotor Abnormalities in Rats
por: Pan, Leilei, et al.
Publicado: (2016)

Plasma Orexin-A Levels Do Not Undergo Circadian Rhythm in Young Healthy Male Subjects
por: Mäkelä, Kari A., et al.
Publicado: (2018)

Orexin, orexin receptor antagonists and central cardiovascular control
por: Carrive, Pascal
Publicado: (2013)

PPARα: An emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases
por: Lin, Yijun, et al.
Publicado: (2022)

Early High-Fat Diet Exposure Causes Dysregulation of the Orexin and Dopamine Neuronal Populations in Nonhuman Primates
por: True, Cadence, et al.
Publicado: (2018)

Chaihu-Longgu-Muli decoction improves sleep disorders by restoring orexin-A function in CKD mice
por: Cao, Xin-li, et al.
Publicado: (2023)

Mitoepigenetics and Neurodegenerative Diseases
por: Coppedè, Fabio, et al.
Publicado: (2019)

Targeting the non-classical estrogen pathway in neurodegenerative diseases and brain injury disorders
por: Koszegi, Zsombor, et al.
Publicado: (2022)

Recruitment of hypothalamic orexin neurons after formalin injections in adult male rats exposed to a neonatal immune challenge
por: Campbell, Erin J., et al.
Publicado: (2015)

The Orexin-A-Regulated Akt/mTOR Pathway Promotes Cell Proliferation Through Inhibiting Apoptosis in Pancreatic Cancer Cells
por: Suo, Linna, et al.
Publicado: (2018)

Role of the Vasopressin/Apelin Balance and Potential Use of Metabolically Stable Apelin Analogs in Water Metabolism Disorders
por: Flahault, Adrien, et al.
Publicado: (2017)

GPR35 as a Novel Therapeutic Target
por: MacKenzie, A. E., et al.
Publicado: (2011)

Myokines: Novel therapeutic targets for diabetic nephropathy
por: Yang, Ming, et al.
Publicado: (2022)

FoxO1 as a tissue-specific therapeutic target for type 2 diabetes
por: Teaney, Nicole A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_059k2glmoptc6lmnfa5q6agi7u